Alto Neuroscience, Inc. (ANRO) company profile
Close on Nov 17, 2026Market cap $977.52MP/E –Yield –
About Alto Neuroscience
Pharmaceutical Preparations, SIC 2834
Alto is a clinical-stage biopharmaceutical company that develops targeted therapies for neuropsychiatric conditions. The company utilizes a proprietary precision psychiatry platform that evaluates brain-based biomarkers through electroencephalography, neurocognitive assessments, wearable technology, and genomic data to identify patients likely to benefit from specific interventions. Its clinical development pipeline comprises seven assets, including ALTO-207, ALTO-300, ALTO-100, ALTO-101, and ALTO-203, targeting disorders such as major depressive disorder, bipolar depression, treatment-resistant depression, cognitive impairment associated with schizophrenia, and Parkinson’s disease. Its products are developed for individuals diagnosed with psychiatric and neurological disorders.
The company conducts clinical trials across the United States, having gathered biomarker data from over 2,000 participants across more than 70 clinical sites. Its clinical operations also examine compounds previously evaluated or approved in international regions including Europe and Australia. The provided text does not disclose the location of its corporate headquarters.
Summary of the business section of Alto Neuroscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alto Neuroscience, Inc.
- Founded
- 2019
- Headquarters
- Mountain View, CA
- Address
- 650 Castro Street, Suite 450 94041
- Phone
- (773) 255-5012
- Website
- altoneuroscience.com
- Employees
- 68, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- ANRO
- Exchange
- NYSE
- IPO date
- Feb 5, 2024
- Shares outstanding
- 39M, Aug 7, 2026
- Public float
- $55.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1999480
- CUSIP
- 02157Q109
- ISIN
- US02157Q1094
- FIGI
- BBG00WYFS6R5
- Share class FIGI
- BBG00WYFS6S4
- EIN
- 83-4210124
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amit Etkin | PRESIDENT AND CEO, Director | 833,949 |
| Nicholas Conrad Smith | PRESIDENT AND CFO | 79,060 |
| Adam Savitz | CHIEF MEDICAL OFFICER | 39,851 |
| Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | – |
| Andrew Craig Miller | Director | – |
| Gwill York | Director | 23,917 |
| Christopher Nixon Cox | Director | 588,898 |
| Andrew Dreyfus | Director | – |
| Husseini Manji | Director | – |
| Ramiro Sanchez | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Amit Etkin, M.D., Ph.D. President, Chief Executive Officer, and Chair of the Board | $650.67K | – | $934.19K | $358.07K | $25.56K | $2.19M | -46% |
| Nicholas Smith Chief Financial Officer and Chief Business Officer | $493.72K | $220.00K | $594.72K | $222.30K | $10.84K | $1.54M | -23% |
| Michael Hanley Chief Operating Officer | $488.80K | – | $517.60K | $195.52K | $11.01K | $1.21M | -50% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 5, 2024
- Offer price
- $16.00
- Securities offered
- 8,040,000
- Gross proceeds
- $128.64M
- Exchange
- NYSE
- First trading day
- Feb 2, 2024
- First-day close
- $20.70+29.4%
- Lock-up ends (est.)
- Jul 31, 2024
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 68 total employees, including 66 in the United States and two in Australia.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 5, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 30, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?